Press Releases June 2, 2026 02:00 AM

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

Pharming Group to present at 2026 Jefferies Global Healthcare Conference in New York

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
PHAR

Pharming Group announced its participation in the 2026 Jefferies Global Healthcare Conference with CEO Fabrice Chouraqui speaking in a Fireside Chat session. The company, listed on Euronext Amsterdam and Nasdaq, will webcast the presentation, highlighting ongoing engagement with investors and healthcare stakeholders.

Pharming Group to participate in Fireside Chat at  2026 Jefferies Global Healthcare Conference in New York
PHAR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Pharming Group's CEO to participate in a high-profile healthcare conference addressing investors and industry professionals.
  • The company emphasizes its global presence with dual listings in Amsterdam and Nasdaq, reflecting its outreach to both European and U.S. markets.
  • Pharming focuses on rare and life-threatening diseases through innovative medicines, including biologics and small molecules, impacting the biotech and pharmaceutical sectors.

Leiden, the Netherlands, June 2, 2026: Pharming Group (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New York on June 3-4, 2026.

Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&A session on Thursday, June 4 at 11:05am EDT/17:05 CEST. A live webcast and replay of the presentation will be made available in the “Events and presentations” and “Our news” sections of Pharming’s website. 

For more information about the conference, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Jefferies representative.

About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Investor Relations
Michael Levitan, VP Investor Relations and Capital Markets
T: +1 (908) 705 1696
E: investor@pharming.com

Media Relations
Global: Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

U.S.: Christina Skrivan (Precision AQ on behalf of Pharming)
T: +1 (636)-352-7883

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

  • Pharming Fireside Chat at Jefferies Healthcare Conference_EN_02JUN2026

Risks

  • Uncertainties regarding the impact of the CEO's conference participation on stock performance as the event mainly serves for investor relations rather than new product news, representing typical market volatility in biotech stocks.
  • Potential regulatory and market risks inherent in developing and commercializing medicines for rare diseases, which may influence investor sentiment in pharmaceutical and healthcare markets.
  • The competitive landscape and pipeline development challenges common in biotech may pose ongoing uncertainties for Pharming's growth and market positioning.

More from Press Releases

GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders Jun 7, 2026 Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026